Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
NEWARK, Calif., Sept. 07, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will participate in a fireside chat at the 2016 Morgan Stanley Global Healthcare Conference scheduled for 2:15 pm ET (11:15 am PT) on Monday, September 12, 2016 in New York, New York.
The fireside chat will be webcast live and may be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the event will be archived for 30 days on the company's website.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
